Structure Therapeutics American Stock Analysis

GPCR Stock   44.52  0.64  1.46%   
Structure Therapeutics American is undervalued with Real Value of 52.39 and Target Price of 83.17. The main objective of Structure Therapeutics stock analysis is to determine its intrinsic value, which is an estimate of what Structure Therapeutics American is worth, separate from its market price. There are two main types of Structure Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Structure Therapeutics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Structure Therapeutics is usually not traded on Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day. Structure Stock trading window is adjusted to America/New York timezone.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Structure Therapeutics American. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

Structure Stock Analysis Notes

About 81.0% of the company shares are owned by institutional investors. The book value of Structure Therapeutics was currently reported as 9.22. The company recorded a loss per share of 2.25. Structure Therapeutics had not issued any dividends in recent years. To learn more about Structure Therapeutics American call Raymond Stevens at (650) 457-1978 or check out

Structure Therapeutics Investment Alerts

Structure Therapeutics is way too risky over 90 days horizon
Structure Therapeutics appears to be risky and price may revert if volatility continues
Structure Therapeutics has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (89.54 M) with profit before overhead, payroll, taxes, and interest of 0.
Structure Therapeutics generates negative cash flow from operations
Over 81.0% of the company shares are owned by institutional investors
Latest headline from The 3 Most Undervalued Biotech Stocks to Buy in July 2024

Structure Therapeutics Upcoming and Recent Events

4th of April 2024
Upcoming Quarterly Report
9th of May 2024
Next Financial Report
31st of December 2023
Next Fiscal Quarter End
4th of April 2024
Next Fiscal Year End
30th of September 2023
Last Quarter Report
31st of December 2022
Last Financial Announcement

Structure Largest EPS Surprises

Earnings surprises can significantly impact Structure Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Structure Therapeutics Environmental, Social, and Governance (ESG) Scores

Structure Therapeutics' ESG score is a quantitative measure that evaluates Structure Therapeutics' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Structure Therapeutics' operations that may have significant financial implications and affect Structure Therapeutics' stock price as well as guide investors towards more socially responsible investments.

Structure Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.1 B.

Management Efficiency

Structure Therapeutics has return on total asset (ROA) of (0.2043) % which means that it has lost $0.2043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2933) %, meaning that it created substantial loss on money invested by shareholders. Structure Therapeutics' management efficiency ratios could be used to measure how well Structure Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The analysis of Structure Therapeutics' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Structure Therapeutics' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Structure Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Return On Assets
Return On Equity

Technical Drivers

As of the 16th of July 2024, Structure Therapeutics has the Risk Adjusted Performance of 0.0336, coefficient of variation of 2475.18, and Semi Deviation of 3.22. Structure Therapeutics technical analysis provides you with a way to harness past market data to determine a pattern that measures the direction of the company's future prices. Please validate Structure Therapeutics variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Structure Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 44.52 per share. Given that Structure Therapeutics has jensen alpha of 0.2932, we advise you to double-check Structure Therapeutics American's current market performance to make sure the company can sustain itself at a future point.

Structure Therapeutics Price Movement Analysis

Execute Study
The output start index for this execution was nine with a total number of output elements of fifty-two. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Structure Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Structure Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.

Structure Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Structure Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Structure Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Structure Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Structure Therapeutics Predictive Daily Indicators

Structure Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Structure Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Structure Therapeutics Corporate Filings

27th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
14th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
13th of June 2024
The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock
12th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
6th of June 2024
Other Reports
5th of June 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
3rd of June 2024
Report filed with the SEC to announce major events that shareholders should know about
30th of May 2024
The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934

Structure Therapeutics Forecast Models

Structure Therapeutics' time-series forecasting models are one of many Structure Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Structure Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Current Structure Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Structure analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Structure analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
83.17Strong Buy10Odds
Structure Therapeutics American current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Structure analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Structure stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Structure Therapeutics, talking to its executives and customers, or listening to Structure conference calls.
Structure Analyst Advice Details

Structure Stock Analysis Indicators

Structure Therapeutics American stock analysis indicators help investors evaluate how Structure Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Structure Therapeutics shares will generate the highest return on investment. By understating and applying Structure Therapeutics stock analysis, traders can identify Structure Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow26.1 M
Common Stock Shares Outstanding36.7 M
Total Stockholder Equity453 M
Tax Provision236 K
Property Plant And Equipment Net8.4 M
Cash And Short Term Investments467.3 M
Cash129.8 M
Accounts Payable4.7 M
Net Debt-124.3 M
50 Day M A41.2726
Total Current Liabilities24.7 M
Other Operating Expenses102.7 M
Non Current Assets Total8.4 M
Non Currrent Assets Other45 K
Stock Based Compensation8.2 M

Additional Tools for Structure Stock Analysis

When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.